Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 years
Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Carol J. Swallow(University Health Network), Rebecca A. Gladdy(Princess Margaret Cancer Centre), Rick L. Haas(Leiden University Medical Center), Rosalba Miceli(Fondazione IRCCS Istituto Nazionale dei Tumori), Frits van Coevorden(The Netherlands Cancer Institute), Deanna Ng(Mount Sinai Hospital), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), D. Strauß(Royal Marsden Hospital), Charles Honoré(Institut Gustave Roussy), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Winan J. van Houdt(Diakonessenhuis hospital), Nikolaos Vassos(European University Cyprus), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Lorenzo Conti(Fondazione IRCCS Istituto Nazionale dei Tumori), Eberhard Stoeckle(Institut Bergonié), Yvonne Schrage(The Netherlands Cancer Institute)
Cited by 56
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k